Experiences with
Chronic obstructive pulmonary disease (COPD)Related links
Chronic obstructive pulmonary disease (COPD)

HealthUnlocked contains information from NHS Digital, licensed under the current version of the Open Government Licence
49,948 public posts
Quit smoking and be free.
It can also lead to chronic obstructive pulmonary disease (COPD).
Other diseases
Smoking can cause erectile dysfunction, infertility, and skin aging. It can also make it harder for blood to circulate, which can lead to fatigue and irritability.
Want to take advantage of all our features? Just log in!
or
QUESTIONS OFTEN ASKED ABOUT SMOKING.
Smoking causes 84% of deaths from lung cancer and 83% of deaths from chronic obstructive pulmonary disease (COPD).
.
How dangerous is smoking?
Light smoking: Dangerous in any dose. Smoking is the leading preventable cause of death in the United States.
Happy Christmas !! 🎂🎄🧑🎄🔔🎁☃️❄️
Our lung condition flare up advice can be found here:
https://www.asthmaandlung.org.uk/conditions/copd-chronic-obstructive-pulmonary-disease/managing-copd-flare-ups
Best wishes
Helpline Team
World COPD Day
Head to our website to find out more:
https://www.asthmaandlung.org.uk/conditions/copd-chronic-obstructive-pulmonary-disease/what-chronic-obstructive-pulmonary-disease?
Take care
Helpline Team
Christmas Moderator Update 🎄
You can find our asthma attack advice here: https://www.asthmaandlung.org.uk/conditions/asthma/manage/when-call-999-or-111#Whentocall999
Our lung condition flare up advice can be found here: https://www.asthmaandlung.org.uk/conditions/copd-chronic-obstructive-pulmonary-disease/managing-copd-flare-ups
Chemo-free treatment with acalabrutinib can benefit CLL/SLL patients never treated before: a plain language summary of the ELEVATE-TN study
The ELEVATE-TN international study commenced in September 2015. The plain language article illustrates how this clinical trial was established and run to determine whether targeted therapy arms using acalabrutinib, a Bruton's Tyrosine Kinase inhibitor ( BTKi), with or without obinutuzumab, would outperform
Improving Treatment Options for Patients with Double Refractory CLL - patients who progressed after treatment with both cBTKis and BCL2i
[i] Abstract[/i]
[i][/i]
[i]The proliferation and survival of chronic lymphocytic leukemia (CLL) cells are heavily dependent on B-cell receptor (BCR) signaling and resistance to apoptosis. Approvals of multiple covalent Bruton's tyrosine kinas inhibitors (cBTKis) as well as the B-cell lymphoma